Topics

Sierra nets $98.4mm in preferred stock public offering tied to agreement for Gilead's momelotinib

14:40 EST 8 Nov 2019 | Elsevier Business Intelligence

Sierra Oncology Inc. netted $98.4mm through the sale of 103k Series A convertible preferred shares (each converts into TK com...

Original Article: Sierra nets $98.4mm in preferred stock public offering tied to agreement for Gilead's momelotinib

NEXT ARTICLE

More From BioPortfolio on "Sierra nets $98.4mm in preferred stock public offering tied to agreement for Gilead's momelotinib"

Quick Search

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...